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Objectives: Advantages of thoracoscopic lobectomy include less postoperative pain, shorter hospitalization, and
improved delivery of adjuvant chemotherapy. The incidence of postoperative complications has not been
thoroughly assessed. This study analyzes morbidity after lobectomy to compare the thoracoscopic approach
and thoracotomy.
Methods: By using a prospective database, the outcomes of patients who underwent lobectomy from 1999–2009
were analyzed with respect to postoperative complications. Propensity-matched groups were analyzed based on
preoperative variables and stage.
Results: Of the 1079 patients in the study, 697 underwent thoracoscopic lobectomy, and 382 underwent lobec-
tomy by means of thoracotomy. In the overall analysis thoracoscopic lobectomy was associated with a lower
incidence of atrial fibrillation (P ¼ .01), atelectasis (P ¼ .0001), prolonged air leak (P ¼ .0004), transfusion
(P¼ .0001), pneumonia (P¼ .001), sepsis (P¼ .008), renal failure (P¼ .003), and death (P¼ .003). In the pro-
pensity-matched analysis based on preoperative variables, when comparing 284 patients in each group, 196
(69%) patients who underwent thoracoscopic lobectomy had no complications versus 144 (51%) patients
who underwent thoracotomy (P ¼ .0001). In addition, thoracoscopic lobectomy was associated with a lower
incidence of atrial fibrillation (13% vs 21%, P ¼ .01), less atelectasis (5% vs 12%, P ¼ .006), fewer prolonged
air leaks (13% vs 19%, P ¼ .05), fewer transfusions (4% vs 13%, P ¼ .002), less pneumonia (5% vs 10%,
P ¼ .05), less renal failure (1.4% vs 5%, P ¼ .02), shorter chest tube duration (median of 3 vs 4 days,
P< .0001), and shorter length of hospital stay (median of 4 vs 5 days, P< .0001).
Conclusions: Thoracoscopic lobectomy is associated with a lower incidence of major complications, including
atrial fibrillation, compared with lobectomy by means of thoracotomy. The underlying factors responsible for this
advantage should be analyzed to improve the safety and outcomes of other thoracic procedures.Earn CME credits at
http://cme.ctsnetjournals.org
Thoracoscopic lobectomy has been successfully performed
worldwide for more than a decade, has emerged as a reason-
able option for the management of early-stage non–small
cell lung cancer (NSCLC), and is supported by evidence-
based treatment guidelines.1-4 Advantages of thoracoscopic
lobectomy compared with thoracotomy include less postop-
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delivery of adjuvant chemotherapy to eligible patients.9,10
Despite these outcomes, the advantages of thoracoscopic
lobectomy appear to be underestimated. From 1999–2006,
only 20% of all lobectomies for NSCLC were performed
thoracoscopically by the board-certified thoracic surgeons
participating in the general thoracic surgery component of
the Society of Thoracic Surgeons database.11 Recently, mor-
bidity and mortality after thoracoscopic lobectomy have
been assessed, demonstrating improved results for some
but not all outcomes.12-14 In the present study postoperative
morbidity and mortality after lobectomy are analyzed by us-
ing a large, prospectively managed database to compare out-
comes after the thoracoscopic approach and thoracotomy by
using a propensity-matched analysis.
MATERIALS AND METHODS
Patient Selection
After obtaining approval from the institutional review board and waivers
of informed consent, a prospectively maintained database of all patients who
underwent lobectomy between February 1999 and October 2008 was que-
ried. Subsequently, a retrospective review of all prospectively collected
data was performed for each individual case. The sources of information
that were reviewed included the institutional Society of Thoracic Surgeonsardiovascular Surgery c Volume 138, Number 2 419
General Thoracic Surgery Villamizar et al
G
T
SAbbreviations and Acronyms
AF ¼ atrial fibrillation
MI ¼ myocardial infarction
NSCLC ¼ non–small cell lung cancer
database, the preoperative clinic note, preoperative studies, the operative
note, the discharge summary, and the surgical pathology report. Baseline
variables collected included demographics, comorbidities, pulmonary func-
tion, induction therapy use, and the use of b-blockers. Primary outcomes as-
sessed were postoperative complications, length of stay, and death.
In general, patients considered appropriate for the thoracoscopic ap-
proach included those with tumors smaller than 6 cm in diameter and with-
out evidence of chest wall or central airway involvement on preoperative
imaging. However, some patients who would have been candidates for thor-
acoscopic resection by one surgeon might not have been considered such by
all surgeons, and the decision to use either the minimally invasive or open
approach was made by the individual surgeon. All patients in this series had
an anatomic lobectomy. Excluded were patients who underwent a lesser
resection (exploration, wedge, or segmentectomy) or a more extensive
operation (pneumonectomy, sleeve lobectomy, chest wall resection, bron-
choplasty, or major vascular resection).
Postoperatively, patients were followed by the operative team, including
data managers who prospectively entered all complications in the database.
All patients underwent continuous electrocardiographic telemetry until
discharge from the hospital. Atrial fibrillation (AF) was defined by an irregular
rhythm with absent P waves. Patients were considered to have AF if the
episode lasted more than 5 minutes, as determined by means of continuous
telemetry. Most cases of AF were confirmed by using 12-lead electrocardio-
graphic analysis. Atelectasis was considered a complication if it prompted
bronchoscopy. A prolonged air leak was defined as an air leak present on post-
operative day 5. Bleeding was considered a complication if it required reop-
eration. Pneumonia was defined as meeting 3 of 5 characteristics: fever,
leukocytosis, chest radiographic scan with infiltrate, positive culture from
sputum, or treatment with antibiotics. The diagnosis of sepsis was recorded
for patients with positive blood culture results. Renal failure was defined as
an increase of serum creatinine to greater than 2.0 and 2 times the most recent
preoperative creatinine level or a new requirement for dialysis postopera-
tively. Myocardial infarction (MI) was defined by an increase in troponin level
to greater than the 99th percentile of the upper reference limit together with at
least 1 of the following: symptoms of ischemia, new ST-T changes or new left
bundle branch block, development of Q waves, or imaging evidence of new
loss of viable myocardium or new regional wall motion abnormality. The
presence of deep venous thrombosis was diagnosed with a lower extremity
Doppler study, and the presence of pulmonary embolism was diagnosed
with a V/Q scan, angiogram, or spiral computed tomographic scan.
Surgical Technique and Postoperative Care
In this series all patients underwent complete anatomic lobectomy and
mediastinal lymph node dissection. Conventional lobectomy was performed
by using a posterolateral thoracotomy without routine sectioning of a rib; the
serratus anterior muscle was spared in all patients, and the latissimus dorsi
muscle was spared also in a minority of patients. Mediastinal lymph node
dissection at thoracotomy and thoracoscopy included the dissection of all
hilar lymph nodes and at least 3 ipsilateral mediastinal lymph node stations.
Thoracoscopic lobectomy was performed as previously described.15
Briefly, 2 incisions were used in most patients in this series. The thoraco-
scope was placed in the seventh or eighth intercostal space in the midaxillary
line, and an anterior utility incision was used in the fifth intercostal space
anteriorly (4–5 cm). This provided access for complete hilar and mediastinal
dissection. Rib spreading, rib cutting, and retractor use were avoided in all
patients undergoing thoracoscopic lobectomy. The established criterion for420 The Journal of Thoracic and Cardiovascular Surconversion to thoracotomy was an intraoperative finding or the occurrence
of an intraoperative event that the surgeon deemed would be managed more
effectively with a thoracotomy. Patients in the thoracoscopy group who
were converted to thoracotomy intraoperatively were kept in the thoraco-
scopy group for the purposes of this analysis.
In general, patients were managed postoperatively according to the same
care map plan, irrespective of whether the procedures were performed open
or thoracoscopically. Management of chest tubes was similar in both
groups, with removal if no air leak was present and drainage was less
than 250 mL/d, although there were minor surgeon-specific preferences.
Discharge criteria were similar as well.
Statistical Analysis
Summary statistics were constructed with the use of frequencies and pro-
portions for categorical data and means, medians, and interquartile ranges
for continuous variables. We compared the characteristics of patients who
underwent their operations through a thoracoscopy with those who had a lo-
bectomy through a thoracotomy. Fisher’s tests and t tests were used to assess
the relationship between treatment through a thoracoscopy or thoracotomy
when data were dichotomous or distributed normally. The Wilcoxon
signed-rank test was used for nonnormally distributed data (chest tube
days and length of stay).
Patient matching based on propensity scores was used to account for
baseline differences between groups. A nonparsimonious logistic regression
model, in which lobectomy through a thoracoscopy or thoracotomy was the
dependent variable and variables in Table 1 were the independent variables,
was constructed. Patients who required conversion to thoracotomy were an-
alyzed by using the intent-to-treat method. With this model, a propensity
score quantifying the likelihood of thoracoscopic lobectomy was calculated
for all patients. Patients who received a lobectomy through a thoracoscopy
TABLE 1. Patient characteristics in 1079 patients undergoing
lobectomy
Characteristics
THOR
(n ¼ 382)
VATS
(n ¼ 697) P value
Age, y 64  11 67  10 .0005
Male/female sex, n 215/167 344/353 .03
Preoperative chemotherapy, n (%) 102 (27) 62 (9) .0001
Preoperative radiotherapy, n (%) 85 (22) 53 (8) .0001
HTN, n (%) 193 (51) 384 (55) .16
MI, n (%) 27 (7) 57 (8) .55
CAD, n (%) 74 (19) 144 (21) .64
CHF, n (%) 18 (5) 30 (4) .76
Atrial fibrillation, n (%) 17 (4) 45 (6) .22
DM, n (%) 71 (19) 99 (14) .07
FEV1,% predicted 67  19 73  29 .0001
DLCO,% predicted 71  20 78  30 .0001
Preoperative b-blocker, n (%) 73 (19) 128 (18) .81
Clinical stage, n (%) .003*
Benign 29 (8) 42 (6)
1 233 (61) 529 (76)
2 37 (10) 39 (6)
3 54 (14) 39 (6)
4 3 (1) 3 (0.4)
Metastasis 23 (6) 42 (6)
Small cell lung cancer 3 (1) 3 (0.4)
Data are presented as means  standard deviations, where shown. THOR, Conven-
tional thoracotomy; VATS, video-assisted thoracoscopic surgery; HTN, hypertension;
MI, myocardial infarction; CAD, coronary artery disease; CHF, congestive heart fail-
ure; DM, diabetes mellitus; FEV1, forced expiratory volume in 1 second; DLCO, car-
bon monoxide diffusion in the lung. *Mantel–Haenszel c2 test.gery c August 2009
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using a greedy 5-to-1 digit-matching algorithm, we matched each patient
who received lobectomy through a thoracoscopy with one patient who
had his or her operation through a thoracotomy starting with all 5-digit pro-
pensity-score matches (ie, to the nearest 0.00001) before moving to those
with 4 or fewer matches in an iterative process. We gave up if there was
no match to at least 1 decimal point.
The matched cohort was evaluated for differences between treatment
groups in each of the potential confounding factors. Postoperative outcomes
from the matched cohorts were then compared by using the Fisher’s test for
categorical outcomes and paired t tests or Wilcoxon signed-rank tests for con-
tinuous variables. Statistics were performed with SAS 9.1 software (SAS In-
stitute, Inc, Cary, NC). The greedy propensity matching was performed with
an SAS macro written by Lori Parsons (accessed in April 2008).16
RESULTS
Patient Characteristics
A review of the prospective database between February
1999 and October 2008 identified 1079 patients who were
eligible for the study. Of these patients, lobectomy was per-
formed by means of thoracoscopy in 697 and by means of
conventional thoracotomy in 382, and characteristics of the
entire group are detailed in Table 1. There were 32 (4.6%)
conversions caused by dense adhesions (14 patients), bleed-
ing (13 patients), technical difficulties (4 patients), and bron-
chial injury (1 patient); these patients are analyzed within the
thoracoscopic lobectomy group.
The mean age was lower in the thoracotomy group (64 vs
67 years, P ¼ .0005). In addition, the thoracoscopic group
had significantly more female patients. The thoracoscopic
group had better forced expiratory volume in 1 second and
carbon monoxide diffusing capacity values. Significantly
more patients in the thoracotomy group received preopera-
tive chemotherapy and radiotherapy. The anatomic distribu-
tion of lobectomy is represented in Table 2.
Patient Outcome: Unmatched
Postoperative outcomes for the entire cohort are detailed in
Table 3. There were 22 (5.8%) deaths among the 382 patients
in the thoracotomy group and 14 (2.0%) deaths among the
697 patients in the thoracoscopic group (P ¼ .003). The
causes of death in the thoracotomy group were the following:
sepsis (7 patients), pneumonia (2 patients), persistent respira-
tory failure (4 patients), cardiac arrest (3 patients), ischemic
bowel and abdominal sepsis (2 patients), cerebrovascular
TABLE 2. Anatomic distribution of lobectomies (n ¼ 1079)
Anatomic distribution
THOR
(n ¼ 382)
VATS
(n ¼ 697)
Right upper lobectomy, n (%) 125 (33) 241 (35)
Right middle lobectomy, n (%) 27 (7) 65 (9)
Right lower lobectomy, n (%) 43 (11) 108 (15)
Right bilobectomy, n (%) 31 (8) 12 (2)
Left upper lobectomy, n (%) 109 (29) 186 (27)
Left lower lobectomy, n (%) 47 (12) 85 (12)
THOR, Conventional thoracotomy; VATS, video-assisted thoracoscopic surgery.The Journal of Thoracic and Cevent (2 patients), and MI (1 patient). In the thoracoscopic
group causes of death were the following: MI (4 patients),
sepsis (3 patients), cerebrovascular event (3 patients), persis-
tent respiratory failure (2 patients), and complications of ce-
rebral edema (1 patient).
In the analysis of individual complications in the entire
cohort, thoracoscopic lobectomy was associated with a lower
incidence of AF (16% vs 22%, P¼ .01), atelectasis (5% vs
12%, P ¼ .0001), prolonged air leak (11% vs 19%, P ¼
.0004), transfusion (4% vs 12%, P ¼ .0001), pneumonia
(4% vs 9%, P ¼ .001), sepsis (0.6% vs 3%, P ¼ .008),
renal failure (2% vs 5%, P ¼ .003), and death (2% vs
6%, P ¼ .003). The proportion of patients not experiencing
any postoperative complication was higher in the thoraco-
scopic group (70% vs 50%, P ¼ .0001). A thoracoscopic
approach also resulted in few chest tube days (median of 3
vs 4 days, P< .0001) and shorter length of stay (median
of 4 vs 5 days, P< .0001).
Patient Outcomes: Propensity Matching
A greedy matching algorithm was used to obtain 2 groups
with similar baseline characteristics to accurately compare
the outcomes of thoracoscopic lobectomy with those of lo-
bectomy by means of thoracotomy. By using this propen-
sity-matched approach, 284 patients from the thoracotomy
group were matched and compared with 284 patients from
the thoracoscopic group based on propensity scores. The
TABLE 3. Overall postoperative complications (n ¼ 1079)
Complication
THOR
(n ¼ 382)
VATS
(n ¼ 697) P value
Atrial fibrillation, n (%) 85 (22) 111 (16) .01
Atelectasis, n (%) 46 (12) 34 (5) .0001
Prolonged air leak, n (%) 73 (19) 77 (11) .0004
Bleeding, n (%) 5 (1.3) 6 (1) .53
Transfusion, n (%) 47 (12) 27 (4) .0001
Wound infection, n (%) 3 (0.8) 1 (0.1) .13
Pneumonia, n (%) 35 (9) 29 (4) .001
Empyema, n (%) 6 (1.6) 4 (0.6) .18
Bronchopleural fistula, n (%) 4 (1) 1 (0.1) .06
Sepsis, n (%) 10 (3) 4 (0.6) .008
Renal failure, n (%) 19 (5) 12 (2) .003
CVA, n (%) 3 (0.8) 3 (0.4) .67
MI, n (%) 2 (0.5) 5 (0.7) 1.0
Ventricular arrhythmia, n (%) 2 (0.5) 5 (0.7) 1.0
DVT, n (%) 2 (0.5) 1 (0.1) .29
PE, n (%) 3 (0.8) 3 (0.4) .67
Chest tube duration, median days
(25th–75th quartile)
4 (3–6) 3 (2–4) .0001*
Length of hospital stay, median days
(25th–75th quartile)
5 (4–7) 4 (3–5) .0001*
Death, n (%) 22 (6) 14 (2) .003
Patients with no complication, n (%) 192 (50) 485 (70) .0001
THOR, Conventional thoracotomy; VATS, video-assisted thoracoscopic surgery; CVA,
cerebrovascular accident; MI, myocardial infarction; DVT, deep venous thrombosis;
PE, pulmonary embolism. *Wilcoxon signed-rank test.ardiovascular Surgery c Volume 138, Number 2 421
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groups are now nearly identical with respect to measured
baseline characteristics (Table 4). The c-statistic for logistic
regression used to generate the propensity model was 0.70.
Postoperative outcomes in these propensity-matched
groups are shown in Table 5. There was no significant differ-
ence in 30-day mortality in the matched groups. The overall
complication rate was lower in patients who underwent thor-
acoscopic lobectomy: 196 (69%) of 284 patients who under-
went thoracoscopic lobectomy had no complications in
comparison with only 144 (51%) of 284 patients who under-
went lobectomy by means of thoracotomy (P ¼ .0001). In
addition, thoracoscopic lobectomy was associated with
a lower incidence of AF (13% vs 21%, P ¼ .01), less atel-
ectasis (5% vs 12%, P ¼ .006), fewer prolonged air leaks
(13% vs 19%, P ¼ .05), fewer transfusions (4% vs 13%,
P ¼ .002), less pneumonia (5% vs 10%, P ¼ .05), and
less renal failure (1.4% vs 5%, P ¼ .02). Finally, thoraco-
scopic lobectomy was associated with shorter chest tube du-
ration (median of 3 vs 4 days, P<.0001) and shorter length
of hospital stay (median of 4 vs 5 days, P< .0001).
DISCUSSION
Many advantages of thoracoscopic lobectomy are well es-
tablished, including issues surrounding postoperative pain,
TABLE 4. Patient characteristics after propensity score–based
matching (n ¼ 568)
Characteristics
THOR
(n ¼ 284)
VATS
(n ¼ 284) P value
Age, y 65  11 65  10 .86
Male/female sex, n 159/125 155/129 .80
Preoperative chemotherapy, n (%) 50 (18) 49 (17) 1.0
Preoperative radiotherapy, n (%) 35 (12) 40 (18) .62
HTN, n (%) 150 (53) 142 (50) .56
MI, n (%) 20 (7) 22 (8) .87
CAD, n (%) 59 (21) 57 (20) .92
CHF, n (%) 12 (4) 12 (4)
Atrial fibrillation, n (%) 13 (5) 10 (5) .67
DM, n (%) 53 (19) 47 (17) .58
FEV1,% predicted 68  19 67  22 .72
DLCO,% predicted 72  20 72  21 .87
Preoperative b-blocker, n (%) 56 (20 50 (18) .59
Clinical stage, n (%) .86*
Benign 22 (8) 15 (5)
1 183 (64) 199 (70)
2 29 (10) 21 (7)
3 31 (11) 24 (8)
4 2 (1) 3 (1)
Metastasis 14 (5) 22 (8)
Small cell lung cancer 3 (1) 0
Data are presented as means  standard deviations, where shown. THOR, Conven-
tional thoracotomy; VATS, video-assisted thoracoscopic surgery; HTN, hypertension;
MI, myocardial infarction; CAD, coronary artery disease; CHF, congestive heart fail-
ure; DM, diabetes mellitus; FEV1, forced expiratory volume in 1 second; DLCO, car-
bon monoxide diffusion in the lung. *Mantel–Haenszel c2 test.422 The Journal of Thoracic and Cardiovascular Sulength of hospital stay, pulmonary function, inflammatory
response, and recovery.1-3,5-8 In addition, thoracoscopic lo-
bectomy is associated with superior delivery of adjuvant
chemotherapy,9,10 which has been demonstrated to improve
survival in patients with breast cancer17,18 and thus might
also improve survival in patients with lung cancer (although
this has not yet been established). A recent review does dem-
onstrate that oncologic outcomes of thoracoscopic lobec-
tomy are equivalent to those of lobectomy by means of
thoracotomy.19
It has also been recognized that thoracoscopic lobectomy
might also be associated with fewer postoperative complica-
tions. Compared with recent published results with lobec-
tomy by means of thoracotomy,20 morbidity associated
with thoracoscopic lobectomy in published series is compa-
rable or superior.2,3,5,7 However, it is difficult to draw mean-
ingful conclusions from comparisons of outcomes among
series that include only one or the other approach.
The observation that thoracoscopic lobectomy might
have a lower complication profile has recently been sup-
ported in studies analyzing outcomes of series including
patients undergoing thoracoscopic lobectomy and patients
undergoing open lobectomy. In one study 122 patients
TABLE 5. Postoperative complications after propensity score–based
matching (n ¼ 568)
Complication
THOR
(n ¼ 284)
VATS
(n ¼ 284) P value
Atrial Fibrillation, n (%) 61 (21) 37 (13) 0.01
Atelectasis, n (%) 34 (12) 15 (5) 0.006
Prolonged air leak, n (%) 55 (19) 37 (13) 0.05
Bleeding, n (%) 3 (1) 3 (1)
Transfusion, n (%) 36 (13) 11 (4) 0.002
Wound infection, n (%) 3 (1) 1 (0.4) 0.62
Pneumonia, n (%) 27 (10) 14 (5) 0.05
Empyema, n (%) 2 (0.8) 2 (0.8)
Bronchopleural Fistula, n (%) 3 (1) 1 (0.4) 0.62
Sepsis, n (%) 6 (2) 1 (0.4) 0.12
Renal Failure, n (%) 15 (5) 4 (1.4) 0.02
CVA, n (%) 3 (1) 2 (1) 1.0
MI, n (%) 0 (0) 1 (0.4) 0.50
Ventricular arrhythmia, n (%) 2 (0.8) 2 (0.8)
DVT, n (%) 2 (0.8) 0 (0) 0.50
PE, n (%) 3 (1) 1 (0.4) 0.62
Chest Tube
duration, median
days (25th, 75th quartile)
4 (3,6) 3 (2,4) 0.0001*
Length of hospital
stay, median
days (25th, 75th quartile)
5 (4,7) 4 (3,6) 0.0001*
Death, n (%) 15 (5) 8 (3) 0.20
Patients with
no complication, n (%)
144 (51) 196 (69) 0.0001
THOR, Conventional thoracotomy; VATS, video-assisted thoracoscopic surgery; CVA,
cerebrovascular accident; MI, myocardial infarction; DVT, deep venous thrombosis;
PE, pulmonary embolism. *Wilcoxon signed-rank test.rgery c August 2009
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dergoing thoracotomy were compared.12 Overall, the inci-
dence of postoperative complications was lower in the
thoracoscopic group (17.2% vs 27.9%, P ¼ .046); how-
ever, these patients were matched for age and sex only,
and there was no significant difference in the incidence
of any of the specific complications reported. In a second
study focusing on elderly patients (age 70 years), a retro-
spective, matched case-control study was performed evalu-
ating the perioperative outcomes after lobectomy by means
of thoracoscopy and thoracotomy.13 After matching based
on age, sex, the presence of comorbid conditions, and pre-
operative clinical stage, there were 82 patients in each
group. Thoracoscopic lobectomy resulted in a significantly
lower rate of complications compared with thoracotomy
(28% vs 45%, P ¼ .04). However, this series was limited
to patients with clinical stage I NSCLC, and the incidence
of several specific complications analyzed individually was
not significantly different between the 2 groups. Whitson
and colleagues21 analyzed the outcomes of an unmatched
group of 147 patients who underwent lobectomy, including
88 by means of thoracotomy and 59 by means of thoraco-
scopy. Thoracoscopic lobectomy was associated with
a lower incidence of pneumonia but no difference in other
complications, including blood loss, AF, or number of ven-
tilator-dependent days.
In the current study the outcomes of patients undergoing
either thoracoscopic lobectomy (n ¼ 697) or open lobec-
tomy (n ¼ 382) were analyzed by using a prospective out-
comes database. The hypothesis of the study was that an
analysis of a larger population would demonstrate improved
outcomes overall in the thoracoscopic group, including im-
proved outcomes with specific complications, such as AF. In
the entire cohort of 1079 patients, thoracoscopic lobectomy
was associated with a lower incidence of AF, atelectasis,
prolonged air leak, transfusion, pneumonia, sepsis, renal
failure, overall complications, and death. Conclusions
from this comparison are limited because of a number of dif-
ferences in baseline patient characteristics.
To improve the analysis, a propensity-matching method
was used to create 2 groups with similar baseline character-
istics based on 13 preoperative variables, including clinical
stage, comparing 284 patients who underwent thoracotomy
and 284 patients who underwent thoracoscopic lobectomy.
The overall complication rate was lower in patients who un-
derwent thoracoscopic lobectomy: 196 (69%) of 284 pa-
tients who underwent thoracoscopic lobectomy had no
complications in comparison with only 144 (51%) of 284
patients who underwent lobectomy by means of thoracot-
omy. In addition, thoracoscopic lobectomy was associated
with a lower incidence of AF (13% vs 21%), less atelectasis
(5% vs 12%), fewer prolonged air leaks (13% vs 19%),
fewer transfusions (4% vs 13%), less pneumonia (5% vs
10%), less renal failure (1.4% vs 5%), shorter chest tubeThe Journal of Thoracic andduration (median of 3 vs 4 days), and shorter length of
hospital stay (median of 4 vs 5 days).
This study demonstrates that thoracoscopic lobectomy is
associated with fewer overall complications than lobectomy
by means of thoracotomy by using propensity-matched
populations based on preoperative variables and on stage.
Patients who underwent thoracoscopic lobectomy had a bet-
ter chance of having no complications and a lower incidence
of AF, an established risk factor for length of stay, and other
complications after lobectomy.22 In addition, thoracoscopic
lobectomy was associated with a lower incidence of
atelectasis, prolonged air leaks, transfusions, pneumonia,
and renal failure. Consistent with other studies,2,3,5-8,12,13
thoracoscopic lobectomy was associated with a shorter chest
tube duration and length of hospital stay.
There are several implications based on these conclu-
sions. First, the underlying factors responsible for the advan-
tage of the minimally invasive strategy should be analyzed,
which might be used to improve the safety and outcomes of
other thoracic procedures. Although it could be assumed that
rib spreading accounts for increased postoperative pain and
that other outcome differences follow, this has not been
demonstrated experimentally.23 Furthermore, although post-
operative pain might influence some outcome variables,
there could be other more important factors that relate to
the lower incidence of AF and the higher fraction of patients
with no complications.
In addition, the lower complication profile of thoraco-
scopic lobectomy might improve the development of risk
assessment algorithms and patient selection.24 Patients
who are currently deemed medically inoperable based on
age, pulmonary function, or other factors might, in fact,
be acceptable candidates for thoracoscopic lobec-
tomy.5,25,26 Finally, despite concerns regarding ultimate
outcomes after thoracoscopic lobectomy, it is possible
that this approach might be associated with superior
overall outcomes, considering the improvement in postop-
erative morbidity demonstrated by this and other stud-
ies,12-14 as well as the improvement in the delivery of
adjuvant therapy.9,10
The conclusions of the current study might be limited by
the nature of reviewing a single-institution, nonrandomized
series, although the propensity-matching approach allows
for analysis of similar groups of patients. This study does
not recreate the conditions of a prospective randomized trial;
it attempts to analyze the outcomes of 2 operative strategies
by using propensity matching to minimize bias in the 2
groups. Because this is a retrospective analysis, it is possible
that the capturing of complications might be incomplete;
however, the analysis used a database that includes compli-
cations that are recorded prospectively. It is also possible
that other open techniques using anterior thoracotomy might
be associated with better outcomes than a posterolateral tho-
racotomy, as used in this series; however, when comparedCardiovascular Surgery c Volume 138, Number 2 423
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thoracotomy was associated with more pain.9
In summary, this study suggests that the probability of
having no postoperative complications after lobectomy is
better with the thoracoscopic approach when compared
with the conventional thoracotomy approach. Thoracoscopic
lobectomy is also associated with a lower incidence of post-
operative AF and several other major complications. These
data suggest that the outcomes of patients with early-stage
NSCLC would be improved by using the thoracoscopic ap-
proach. The underlying factors responsible for this advantage
should be analyzed, which might be used to improve the
safety and outcomes of other thoracic procedures.
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Discussion
Dr John Mitchell (Denver, Colo). Dr Fullerton, members, and
guests, I would like to congratulate Dr Villamizar and his colleagues
on a very nice presentation and a well-written manuscript. In this
study you describe a lower incidence of postoperative complications
after thoracoscopic lobectomy compared with open lobectomy in
patients with lung cancer both in a retrospective analysis of a consec-
utive series of patients undergoing lobectomy and in a propensity-
matched analysis. The third portion that you presented today with
the propensity matching based on stage was not in the manuscript
I received, and therefore I will not address that per se.
I would guess that in the first overall analysis most of the differ-
ences in outcome could be explained by differences in the 2 patient
groups, such as the percentage undergoing induction therapy. In the
matched analysis there was a greater percentage of patients with no
complications, less AF, shorter hospital stays, and a shorter but
clinically insignificant chest tube duration.
Your findings frankly mirror my own observations with thoraco-
scopic lobectomy, but I have a few questions for you.
First, I was wondering if you could tell us what effect the loca-
tion or the type of lobectomy that you performed had on the com-
plication rates. Were right upper lobes associated with greater
complication rates than middle lobes or lower lobes or vice versa?
Dr Villamizar. We did not address that in our review. However,
both groups underwent the same percentage of right upper lobec-
tomy. In previous series we have not seen an association between
the location of the lobectomy and postoperative complications
and, in this particular case, with AF.
Dr Mitchell. My second question has to do with the stage. I was
going to ask you how the differences in stage between the 2
matched groups had an effect on the outcomes. At least in the
matched series of 153 patients each, a majority of the thoracoscop-
ies, not surprisingly, were done in patients with stage I disease.
Could you expound a little bit more on how the stage has an effect
on the results that you described today?
Dr Villamizar. When we did the propensity-matched analysis,
the idea was to have groups that were comparable in terms of base-
line characteristics. We did find in that first propensity-matched
analysis that the stage was different, and that is why we proceeded
to do another matched analysis, this time based on stage. From thatrgery c August 2009
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Slast matched analysis, it seems that the stage did not affect the in-
cidence of postoperative complications, and it was more the surgi-
cal approach that had a bigger effect.
Dr Mitchell. I had always thought that AF seen in conjunction
with lobectomy was due to manipulation of the pulmonary veins or
dissection at the hilum. These factors should have been the same
whether the procedure was done open or thoracoscopically, and
therefore how do you account for less AF in the thoracoscopic group?
Dr Villamizar. That is correct. In our institution the dissection is
similar whether we do it thoracoscopically or through a thoracot-
omy. It is unclear at this point what is causing the AF, but there
is some literature that supports the idea that in the open thoracot-
omy group there is a higher cytokine and inflammatory response
overall, as well as increasing white blood cell count. It is possible
that the cytokines are related to the presence of AF.
Dr Robert Cerfolio (Birmingham, Ala). Congratulations on an
outstanding paper that was very well presented. Can you tell me
your criteria for chest tube removal and why the patients undergo-
ing open lobectomies are in the hospital for 7 days and have chest
tube in for so long, 7 days? I believe this is what has artificially in-
flated the bad results in your open group. What do you use to take
the chest tube out?
Dr Villamizar. If the patient has drainage of less than 200 mL,
even on postoperative day 1, and the patient does not have an air
leak, we will remove the chest tube.
Dr Cerfolio. So you use a very low traditional number. You
have not increased that number to 300 or 400 or 450 mL, as we
have recently published is safe? Is that the thing that is keeping
the chest tube in longer in the open group versus the video-assisted
thoracoscopic surgery group?
Dr Villamizar. Those are the criteria that we use for postoper-
ative day 1 or 2. If the patient does not have a leak and the output
is greater than 200 mL but, let us say, less than 400 mL and the pa-
tient had a thoracoscopic approach, the chest tube would be re-
moved on postoperative day 2 anyway. The reason why there is
a difference between the 2 groups in removing the chest tube is be-
cause in the thoracotomy group the drainage from the chest tube
will be greater than 400 or 500 mL usually.
Dr Cerfolio. This answer shows why the open group did so
poorly in terms of length of stay.
Finally, what would you say to someone like me—and you can
go ahead and give me the business if you want, which is always
fun—who still prefers open lobectomy but sends my patient
home on the third or fourth day, most (ie, 99%) with their chest
tubes out, although some go home with their chest tubes in if
they have an air leak. I am very happy with a rib-sparing, nerve-
sparing, muscle-sparing thoracotomy, and in fact, I think it even
hurts less than my patients undergoing video-assisted thoraco-The Journal of Thoracic andscopic surgery. What would you say to me to convince me to start
doing more video-assisted thoracoscopic surgery lobectomies for
patients with cancer?
Dr Villamizar. We know that you have very good experience
with the thoracotomy approach, and your results are very good.
However, there is strong literature that supports the idea that the
thoracoscopic approach is related to a lower incidence of postoper-
ative complications and, in this study, AF. Even if you remove the
chest tube on the third day and send your patients home at the same
time that you would send home a patient undergoing a thoraco-
scopic approach, it is possible that the incidence of AF and other
complications would be reduced if you were using the thoraco-
scopic approach.
Dr Douglas Wood (Seattle, Wash). I just want to follow up on
Dr Cerfolio’s question. Most of the outcome variables that you
looked at were not affected by providers; however, the variable
of chest tube removal and the variable of hospital discharge are re-
lated to provider decisions. Can you comment on potential provider
biases that might exist in perceiving that patients can have chest
tubes removed earlier or that they can be discharged earlier if
they undergo thoracoscopy and how that might influence those out-
comes in ways that are not related to the procedure itself but are re-
lated to the bias of the providers?
Dr Villamizar. We have noticed over the years that even the
way that our surgeons approach postoperative recovery in the tho-
racotomy group is different based on the experience that we have
acquired with the thoracoscopic group. The surgeons used to re-
move chest tubes at a later day, but now what we see is that the chest
tube is removed at an earlier point, which is reflected in this study
by only a 1-day difference in the median between the 2 groups.
Again, this difference is mostly due to patients who have a larger
volume draining from the chest tube in the thoracotomy group.
Unidentified speaker. I have a quick question. Your study
shows that this operation can be done. The question is this: Should
it be done? At the American Thoracic Society, a paper was pre-
sented that showed there is a statistically significant lower number
of lymph nodes sampled with a video approach from a very high-
volume very well-respected cancer center. Did you look at the num-
ber of nodes harvested with each technique, and did you see any
differences in the pathologic result?
Dr Villamizar. We did not address this question in this study,
but our experience is that the number of nodes removed with the
thoracoscopic approach is the same or is not statistically different
from the number of nodes removed with thoracotomy. In previous
series other groups have also demonstrated this fact, as well as no
differences in overall survival between the 2 surgical techniques.
The survival is comparable or even better with the thoracoscopic
approach.Cardiovascular Surgery c Volume 138, Number 2 425
